From: A longitudinal study on quality of life along the spectrum of Alzheimer’s disease
EQ-5D utilities | VAS | ||||||||
---|---|---|---|---|---|---|---|---|---|
Unadjusted | Model 1 | Model 2 | Model 3 | Unadjusted | Model 1 | Model 2 | Model 3 | ||
Β (SE) | Β (SE) | Β (SE) | Β (SE) | Β (SE) | Β (SE) | Β (SE) | Β (SE) | ||
SCD | Aβ positive | 0.03 (0.02) | 0.03 (0.02) | 0.03 (0.02) | 0.03 (0.02) | 4.81 (2.02)* | 4.57 (2.08)* | 4.03 (2.05)* | 4.06 (1.96)* |
Time * Aβ positive | − 0.01 (0.004)* | − 0.01 (0.004)* | − 0.01 (0.004)* | − 0.01 (0.004)* | − 1.10 (0.45)* | − 1.08 (0.45)* | − 1.08 (0.45)* | − 0.96 (0.45)* | |
MCI | Aβ positive | 0.10 (0.02)* | 0.10 (0.02)* | 0.09 (0.02)* | 0.07 (0.21)* | 7.68 (2.25)* | 7.65 (2.32)* | 6.01 (2.30)* | 4.34 (2.32) |
Time * Aβ positive | − 0.01 (0.004)* | − 0.01 (0.004)* | − 0.01 (0.004)* | − 0.01 (0.004)* | − 1.21 (0.44)* | − 1.19 (0.44)* | − 1.12 (0.44)* | − 1.07 (0.44)* |